Clinical Pathways Endnotes

Clinical Pathways and Documentation

  1. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed March 15, 2021.
  2. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Accessed March 15, 2021.
  3. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(3):872-888. doi: 10.1182/bloodadvances.2020003763
  4. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST
  5. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195-2198. doi: 10.1001/jama.2020.7202
  6. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi: 10.1136/bmj.m1996
  7. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. doi: 10.1371/journal.pmed.1003346
  8. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057
  9. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Centers for Disease Control and Prevention. Accessed March 15, 2021.
  10. Hanson KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. Infectious Diseases Society of America. Accessed March 15, 2021.
  11. Hanson KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. Infectious Diseases Society of America. Accessed April 27, 2021.
  12. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328
  13. Chow DS, Glavis-Bloom J, Soun JE, et al. Development and external validation of a prognostic tool for COVID-19 critical disease. PLoS ONE. 2020;15(12): e0242953. doi: 10.1371/journal.pone.0242953
  14. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339. doi: 10.1136/bmj.m3339
  15. Artero A, Madrazo M, Fernández-Garcés M, et al. Severity scores in COVID-19 pneumonia: a multicenter, retrospective, cohort study. J Gen Intern Med. 2021;36(5):1338-1345. doi: 10.1007/s11606-021-06626-7
  16. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
  17. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — Interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184
  18. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. doi: 10.1038/s41577-020-0311-8
  19. Griffin DO, Brennan-Rieder D, Ngo B, et al. The importance of understanding the stages of COVID-19 in treatment and trials. Aids Rev. 2021;23(1):40-47. doi: 10.24875/AIDSRev.200001261
  20. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2
  21. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLOS Med. 2006;3(9):e343. doi: 10.1371/journal.pmed.0030343
  22. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
  23. Group TRC, Horby PW, Estcourt L, et al. Preprint: Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021; 03.09.21252736. doi: 10.1101/2021.03.09.21252736
  24. CONCOR-1. Press Release: Recruitment for the CONCOR-1 trial is now complete. CONCOR. Accessed April 27, 2021.
  25. REMAP-CAP. Press Release: Convalescent Plasma for COVID-19. REMAP-CAP Trial. Accessed April 27, 2021.
  26. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610-618. doi: 10.1056/NEJMoa2033700
  27. ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384(10):905-914. doi: 10.1056/NEJMoa2033130
  28. Cohen MS. Monoclonal antibodies to disrupt progression of early Covid-19 infection. N Engl J Med. 2021;384(3):289-291. doi: 10.1056/NEJMe2034495
  29. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795-807. doi: 10.1056/NEJMoa2031994
  30. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis. Res Pract Thromb Haemost. 2020;4(7):1178-1191. doi: 10.1002/rth2.12439
  31. Modin D, Claggett B, Sindet-Pedersen C, et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142(21):2080-2082. doi: 10.1161/CIRCULATIONAHA.120.050809
  32. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031
  33. REMAP-CAP, ACTIV-4, ATTACC teams. Press Release: Results of interim analyses of Anticoagulation Domain (multi-platform RCT with ATTACC and ACTIV4 trials). REMAP-CAP Trial. Accessed April 28, 2021. https://www.remapcap.org/media
  34. Caputo ND, Strayer RJ, Levitan R. Early self‐proning in awake, non‐intubated patients in the emergency department: a single ED’s experience during the COVID‐19 pandemic. Acad Emerg Med. 2020;27(5):375-378. doi:10.1111/acem.13994
  35. Elharrar X, Trigui Y, Dols A-M, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA. 2020;323(22):2336-2338. doi: 10.1001/jama.2020.8255
  36. Sartini C, Tresoldi M, Scarpellini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA. 2020;323(22):2338-2340. doi: 10.1001/jama.2020.7861
  37. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629. doi: 10.1172/JCI137244
  38. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. doi: 10.1007/s00134-020-05991-x
  39. Xu B, Fan C, Wang A, et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020;81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012
  40. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3
  41. Nguyen CT, Olson G, Pho MT, et al. Automatic ID consultation for inpatients with COVID-19: point, counterpoint, and a single-center experience. Open Forum Infect Dis. 2020;7(ofaa318). doi: 10.1093/ofid/ofaa318
  42. Abbott J, Johnson D, Wynia M. Ensuring adequate palliative and hospice care during COVID-19 surges. JAMA. 2020;324(14):1393-1934. doi: 10.1001/jama.2020.16843
  43. The Lancet. Palliative care and the COVID-19 pandemic. Lancet. 2020;395(10231):1168. doi: 10.1016/S0140-6736(20)30822-9
  44. Fadul N, Elsayem AF, Bruera E. Integration of palliative care into COVID-19 pandemic planning. BMJ Support Palliat Care. 2021;11(1):40-44. doi: 10.1136/bmjspcare-2020-002364
  45. Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-CoV-2 Infection in Healthcare Settings. Centers for Disease Control and Prevention. Accessed March 15, 2021.